{"id":"https://openalex.org/W3095376360","doi":"https://doi.org/10.1182/blood-2020-141333","title":"Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States","display_name":"Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States","publication_year":2020,"publication_date":"2020-11-05","ids":{"openalex":"https://openalex.org/W3095376360","doi":"https://doi.org/10.1182/blood-2020-141333","mag":"3095376360"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-141333","doi":"https://doi.org/10.1182/blood-2020-141333","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-141333","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088307376","display_name":"Naveen Pemmaraju","orcid":"https://orcid.org/0000-0002-1670-6513","observed_orcids":["https://orcid.org/0000-0002-1670-6513"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naveen Pemmaraju","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087187822","display_name":"Jingbo Yu","orcid":"https://orcid.org/0000-0001-9819-0735","observed_orcids":["https://orcid.org/0000-0001-9819-0735"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jingbo Yu","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039013983","display_name":"Shreekant V. Parasuraman","orcid":"https://orcid.org/0000-0001-8162-8171","observed_orcids":["https://orcid.org/0000-0001-8162-8171"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shreekant Parasuraman","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112693357","display_name":"Anne Shah","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anne Shah","raw_affiliation_strings":["Avalere Health, Washington, DC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avalere Health, Washington, DC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109520642","display_name":"Ann Xi","orcid":"https://orcid.org/0000-0002-7798-6803","observed_orcids":["https://orcid.org/0000-0002-7798-6803"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ann Xi","raw_affiliation_strings":["Avalere Health, Washington, DC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avalere Health, Washington, DC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110816642","display_name":"Shambhavi Kumar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shambhavi Kumar","raw_affiliation_strings":["Avalere Health, Washington, DC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avalere Health, Washington, DC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017460979","display_name":"Robyn Marie Scherber","orcid":"https://orcid.org/0000-0001-7343-5679","observed_orcids":["https://orcid.org/0000-0001-7343-5679"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robyn M. Scherber","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"21","last_page":"21"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/essential-thrombocythemia","display_name":"essential thrombocythemia","score":1.0},{"id":"https://openalex.org/keywords/thrombotic-complications","display_name":"thrombotic complications","score":0.9319999814033508},{"id":"https://openalex.org/keywords/mortality-risk","display_name":"mortality risk","score":0.9789999723434448},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.925000011920929},{"id":"https://openalex.org/keywords/deep-vein-thrombosis","display_name":"deep vein thrombosis","score":0.8640000224113464},{"id":"https://openalex.org/keywords/pulmonary-embolism","display_name":"pulmonary embolism","score":0.996999979019165},{"id":"https://openalex.org/keywords/ischemic-stroke","display_name":"ischemic stroke","score":0.9800000190734863},{"id":"https://openalex.org/keywords/acute-myocardial-infarction","display_name":"acute myocardial infarction","score":0.953000009059906},{"id":"https://openalex.org/keywords/peripheral-arterial-thrombosis","display_name":"peripheral arterial thrombosis","score":0.7910000085830688},{"id":"https://openalex.org/keywords/medicare-beneficiaries","display_name":"Medicare beneficiaries","score":0.5740000009536743},{"id":"https://openalex.org/keywords/older-adults","display_name":"older adults","score":0.746999979019165},{"id":"https://openalex.org/keywords/thrombosis-risk-stratification","display_name":"thrombosis risk stratification","score":0.5680000185966492},{"id":"https://openalex.org/keywords/hydroxyurea","display_name":"hydroxyurea","score":0.6420000195503235},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.9950000047683716}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9177327156066895},{"id":"https://openalex.org/C2781057849","wikidata":"https://www.wikidata.org/wiki/Q1368780","display_name":"Essential thrombocythemia","level":3,"score":0.7383460402488708},{"id":"https://openalex.org/C2776265017","wikidata":"https://www.wikidata.org/wiki/Q220570","display_name":"Pulmonary embolism","level":2,"score":0.6202840805053711},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.534121572971344},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.501288652420044},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.48369938135147095},{"id":"https://openalex.org/C2780868729","wikidata":"https://www.wikidata.org/wiki/Q261327","display_name":"Thrombosis","level":2,"score":0.474776953458786},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.4659987688064575},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.4417974352836609},{"id":"https://openalex.org/C2778959117","wikidata":"https://www.wikidata.org/wiki/Q430892","display_name":"Deep vein","level":3,"score":0.4377826452255249},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.4315221905708313},{"id":"https://openalex.org/C2780645631","wikidata":"https://www.wikidata.org/wiki/Q671554","display_name":"Stroke (engine)","level":2,"score":0.42158159613609314},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.41951489448547363},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.4116032123565674},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4031907021999359},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.2832382023334503},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.21693500876426697},{"id":"https://openalex.org/C78519656","wikidata":"https://www.wikidata.org/wiki/Q101333","display_name":"Mechanical engineering","level":1,"score":0.0},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-141333","doi":"https://doi.org/10.1182/blood-2020-141333","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-141333","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4213170957","https://openalex.org/W3113167806","https://openalex.org/W2554361783","https://openalex.org/W2585187708","https://openalex.org/W4415242523","https://openalex.org/W4311719727","https://openalex.org/W4412419401","https://openalex.org/W1583468714","https://openalex.org/W2980207050","https://openalex.org/W4385702633"],"abstract_inverted_index":{"Background":[0],"Essential":[1],"thrombocythemia":[2],"(ET)":[3],"is":[4,29,693,709],"a":[5,20,67,75,157,253,278,315,324,362,374,452,510,518,534,537,694,710],"myeloproliferative":[6],"neoplasm":[7],"(MPN)":[8],"associated":[9],"with":[10,43,60,101,116,136,156,236,247,249,277,361,407,455,472,502,514,557,562],"an":[11,102,137,521],"increased":[12,447,524],"risk":[13,53,109,244,443,525,554],"of":[14,23,37,47,54,129,141,145,168,171,194,196,231,272,280,359,364,422,444,500,526,697,713],"thrombotic":[15],"events":[16,199],"(TEs),":[17],"which":[18],"represent":[19],"substantial":[21],"cause":[22],"mortality":[24,40,55,243,445,527],"in":[25,41,303,393,425,541,555,560,671,681,727],"this":[26,48,494,542],"population.":[27,543],"There":[28],"limited":[30],"contemporary,":[31,495],"real-world":[32,496],"evidence":[33],"exploring":[34],"the":[35,84,127,130,151,161,192,197,225,229,283,308,327,330,335,394,426],"effect":[36],"TEs":[38,221],"on":[39,111,191],"patients":[42,57,100,155,246,305,312,319,360,406,449,501,513,556],"ET.":[44],"The":[45,123,180,384,418,442],"aim":[46],"analysis":[49],"was":[50,126,178,183,289,301,397,446],"to":[51,98,228,241,390,506,548],"compare":[52],"among":[56,245],"newly":[58,503],"diagnosed":[59,504],"intermediate-":[61,505],"or":[62,107,119,143,218,373],"high-risk":[63,507],"ET":[64,103,133,138,248,281,388,508,515],"who":[65,71,450,457,516,530],"experienced":[66,451,509,517],"TE":[68,186,251,300,316,331,392,424,453,474,485,519,553],"vs":[69,332,341,354,367,371,378,528],"those":[70,414,456,471,482,529,561],"did":[72,321,458,531],"not":[73,322,459,532],"experience":[74,533],"TE.":[76,325,417,511,564],"Study":[77],"Design":[78],"and":[79,154,174,187,260,266,295,317,357,410,437,481,551],"Methods":[80],"All":[81],"data":[82],"from":[83,92,224,387],"Medicare":[85,274],"Fee-for-Service":[86],"(FFS)":[87],"claims":[88],"database":[89],"(Parts":[90],"A/B/D)":[91],"January":[93],"2010-December":[94],"2017":[95],"were":[96,164,222,239,293,297,380,429],"used":[97,240],"identify":[99],"diagnosis":[104,159,279,389],"(all":[105],"intermediate":[106],"high":[108],"based":[110,190],"cohort":[112],"age":[113,288,338],"\u226565":[114],"years)":[115],"\u22651":[117],"inpatient":[118],"\u22652":[120],"outpatient":[121],"claims.":[122],"index":[124,152,226,350],"date":[125,128,153,227],"first":[131,391,423],"qualifying":[132],"claim.":[134],"Patients":[135],"diagnosis,":[139],"use":[140,144],"hydroxyurea,":[142],"ruxolitinib":[146],"within":[147],"12":[148,169],"months":[149,170,399,404,412],"before":[150],"myelofibrosis":[158],"during":[160,200],"study":[162,181,284],"period":[163,396,428],"excluded.":[165],"A":[166,270],"minimum":[167],"continuous":[172],"medical":[173],"pharmacy":[175],"enrollment":[176],"pre-index":[177,258,408,416,473,484],"required.":[179],"sample":[182],"categorized":[184],"into":[185],"non-TE":[188,333],"groups":[189],"occurrence":[193],"any":[195],"following":[198],"follow-up:":[201],"deep":[202],"vein":[203],"thrombosis,":[204,217],"pulmonary":[205],"embolism,":[206],"ischemic":[207,213,430,439],"stroke,":[208],"acute":[209,433],"myocardial":[210,434],"infarction,":[211],"transient":[212,438],"attack,":[214],"peripheral":[215],"arterial":[216],"superficial":[219],"thrombophlebitis.":[220],"evaluated":[223],"end":[230],"follow-up.":[232],"Cox":[233],"regression":[234],"analyses":[235],"time-varying":[237],"effects":[238],"assess":[242],"post-index":[250],"as":[252],"time-dependent":[254],"variable,":[255],"stratified":[256],"by":[257],"TE,":[259,409,535],"adjusting":[261],"for":[262,400,405,413,448,469],"patient":[263],"demographic":[264],"characteristics":[265],"comorbid":[267],"conditions.":[268],"Results":[269],"total":[271],"143,588":[273],"FFS":[275],"beneficiaries":[276],"met":[282],"inclusion":[285],"criteria;":[286],"median":[287,336,385],"76.0":[290],"years,":[291,344],"68.1%":[292],"female,":[294],"84.2%":[296],"white.":[298],"Pre-index":[299],"reported":[302],"37,284":[304],"(26.0%).":[306],"In":[307,326,493],"follow-up":[309,395,427],"period,":[310],"49,497":[311],"(34.5%)":[313],"had":[314,520],"94,091":[318],"(65.5%)":[320],"have":[323],"comparison":[328],"between":[329],"groups,":[334],"(range)":[337],"(77":[339],"[65-107]":[340],"75":[342],"[65-110]":[343],"respectively),":[345],"mean":[346],"(SD)":[347],"Charlson":[348],"comorbidity":[349],"score":[351],"(4.8":[352],"[3.5]":[353],"3.8":[355],"[3.5]),":[356],"percentage":[358],"history":[363],"bleeding":[365],"(27.0%":[366],"22.2%),":[368],"anemia":[369],"(64.7%":[370],"55.9%),":[372],"cardiovascular":[375],"event":[376],"(45.8%":[377],"33.5%)":[379],"higher":[381],"(Table":[382],"1).":[383],"time":[386],"2.8":[398],"all":[401],"patients,":[402],"0.5":[403],"8.0":[411],"without":[415,483],"most":[419],"common":[420],"types":[421],"stroke":[431],"(37.3%),":[432],"infarction":[435],"(23.2%),":[436],"attack":[440],"(22.6%).":[441],"compared":[454],"(hazard":[460],"ratio":[461],"[HR;":[462],"95%":[463],"CI],":[464,477,488],"11.2":[465],"[10.6-11.8];":[466],"P<0.001),":[467],"including":[468],"both":[470],"(HR":[475,486],"[95%":[476,487],"9.3":[478],"[8.6-10.1];":[479],"P<0.001)":[480],"15.4":[489],"[14.2-16.8];":[490],"P<0.001).":[491],"Conclusions":[492],"analysis,":[497],"approximately":[498,522],"one-third":[499],"Elderly":[512],"11-fold":[523],"highlighting":[536],"continued":[538],"unmet":[539],"need":[540],"Further":[544],"efforts":[545],"are":[546],"needed":[547],"better":[549],"define":[550],"mitigate":[552],"ET,":[558],"particularly":[559],"prior":[563],"Disclosures":[565],"Pemmaraju:":[566],"Daiichi":[567],"Sankyo:":[568],"Research":[569,572,575,582,586,592,600,610,629,634,637,643,647,651,659,662,733,737,740,745,749,752,757,762,765,768,771,774,777,781,785],"Funding;":[570,573,576,583,587,593,601,611,630,635,638,644,648,652,660,734,738,741,746,750,753,758,763,766,769,772,775,778,782],"Cellectis:":[571],"Plexxikon:":[574],"Blueprint":[577,759],"Medicines:":[578],"Honoraria;":[579,596,607,614,616,618,621],"AbbVie:":[580],"Honoraria,":[581,599,609],"Samus":[584],"Therapeutics:":[585,598,736],"Affymetrix:":[588],"Other:":[589,624,690,706],"Grant":[590,625],"Support,":[591],"Roche":[594],"Diagnostics:":[595],"Stemline":[597],"Pacylex":[602],"Pharmaceuticals:":[603],"Consultancy;":[604,640,655],"Incyte":[605,631,698,714,742],"Corporation:":[606,632,665,675,689,705,721,743],"Novartis:":[608,747],"LFB":[612],"Biotechnologies:":[613],"MustangBio:":[615],"Celgene:":[617,649,779],"DAVA":[619],"Oncology:":[620,646,654,755],"SagerStrong":[622],"Foundation:":[623],"Support.":[626],"Gerds:Gilead":[627],"Sciences:":[628],"Consultancy,":[633,650,658,744,748,756,780],"Roche/Genentech:":[636],"AstraZeneca/MedImmune:":[639],"Imago":[641],"Biosciences:":[642],"Sierra":[645,754],"Apexx":[653],"CTI":[656],"Biopharma:":[657],"Pfizer:":[661],"Funding.":[663,786],"Yu:Incyte":[664],"Current":[666,668,676,678,686,702,718,722,724],"Employment,":[667,677,723],"equity":[669,679,725],"holder":[670,680,726],"publicly-traded":[672,682,728],"company.":[673,683,729],"Parasuraman:Incyte":[674],"Shah:Avalere":[684],"Health:":[685,701,717],"Employment.":[687,703,719],"Xi:Incyte":[688],"Avalere":[691,700,707,716],"Health":[692,708],"paid":[695,711],"consultant":[696,712],"Corporation;":[699,715],"Kumar:Incyte":[704],"Scherber:Incyte":[720],"Verstovsek:CTI":[730],"Biopharma":[731],"Corp:":[732,761],"Protagonist":[735],"Roche:":[739],"PharmaEssentia:":[751],"Medicines":[760],"Genentech:":[764],"AstraZeneca:":[767],"ItalPharma:":[770],"Promedior:":[773],"Gilead:":[776],"NS":[783],"Pharma:":[784]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}